8-K: Pacira BioSciences Reports Q2 2026 Results

Pacira BioSciences announced second quarter 2026 financial results, reporting total revenue of $192.4 million, a 6% year-over-year increase, alongside strategic advancements including the iovera divestiture and EXPAREL reimbursement expansion.

Summary

• Pacira BioSciences reported second quarter 2026 total revenue of $192.4 million, a 6% increase compared to $181.1 million in the second quarter of 2025.
• EXPAREL net product sales reached $147.8 million, a 3% increase year-over-year.
• ZILRETTA net product sales were $32.6 million, a 4% increase year-over-year.
• The company completed the divestiture of its iovera business to Zimmer Biomet for up to $140 million, closing on July 31, 2026.
• UnitedHealthcare has begun providing separate reimbursement for EXPAREL in outpatient settings.
• The development program for PCRX-201, a gene therapy for osteoarthritis, has transitioned to a scalable commercial manufacturing process.
• Second quarter GAAP net income was $4.7 million ($0.12 per share), compared to a net loss of $4.8 million ($0.11 per share) in Q2 2025.
• Second quarter adjusted EBITDA was $48.7 million, down from $54.3 million in Q2 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive report, with solid revenue growth and strategic progress, though some key metrics like adjusted EBITDA show a year-over-year decrease.

Positives

• Total revenue increased by 6% year-over-year to $192.4 million.
• EXPAREL net product sales grew 3% to $147.8 million.
• ZILRETTA net product sales increased by 4% to $32.6 million.
• The divestiture of iovera to Zimmer Biomet provides potential future revenue and preserves Pacira's participation in its success.
• UnitedHealthcare's separate reimbursement for EXPAREL expands patient access.
• The PCRX-201 gene therapy program is advancing with a scalable manufacturing process and enrollment in Phase 2 study.
• A real-world study presented at ISPOR 2026 highlighted EXPAREL's benefits in Total Shoulder Arthroplasty (TSA) procedures, including lower opioid consumption and reduced healthcare costs.
• The company reported a positive GAAP net income of $4.7 million, a significant improvement from the net loss in the prior year.

Negatives

• Adjusted EBITDA decreased to $48.7 million from $54.3 million in the prior year's second quarter.
• Non-GAAP net income decreased to $29.5 million ($0.73 per diluted share) from $36.0 million ($0.74 per diluted share) in Q2 2025.
• Total operating expenses increased to $188.1 million from $172.6 million in the prior year's second quarter.
• The full-year revenue guidance has been slightly reduced to $735 million $760 million from $745 million $770 million, reflecting the iovera divestiture.

Risks

• Risks associated with acquisitions, such as integration challenges and failure to achieve expected benefits.
• Risks associated with divestitures.
• Manufacturing and supply chain disruptions.
• Global and United States economic conditions, including inflation and rising interest rates.
• Market acceptance and commercial success of EXPAREL and ZILRETTA.
• Timing and success of clinical trials for EXPAREL, ZILRETTA, and other product candidates like PCRX-201.
• Regulatory approvals for new indications or in other jurisdictions.
• Potential litigation outcomes and recoverability of deferred tax assets.

Future Outlook

The company updated its full-year 2026 guidance to reflect the iovera divestiture, projecting total revenue between $735 million and $760 million. Guidance for non-GAAP SG&A expense and stock-based compensation was also adjusted. Key guidance for EXPAREL net product sales ($600-$620 million), non-GAAP gross margin (77%-79%), and non-GAAP R&D expense ($105-$115 million) were reiterated.

Management Comments

• "The first half of 2026 was marked by solid revenue growth and strong execution of our 5x30 strategy across the business."
• "Just 18 months into the initiative, we are delivering meaningful progress against each of our strategic objectives to drive long-term growth and create significant value."
• "The quarter was also highlighted by our recently closed transaction with Zimmer Biomet, which positions iovera to reach its full global potential while preserving Pacira's participation in its future success and further sharpening our focus as an innovation-driven biopharmaceutical company."

Industry Context

StockSavvy.ai notes that Pacira BioSciences continues to focus on its non-opioid pain therapies, a growing area driven by the opioid crisis and demand for safer alternatives. The expansion of EXPAREL reimbursement by a major insurer like UnitedHealthcare is a significant positive development, indicating broader market acceptance. The advancement of PCRX-201, a gene therapy for osteoarthritis, aligns with industry trends towards innovative, potentially curative treatments for chronic conditions.

Comparison to Industry Standards

• EXPAREL's reported 6% year-over-year revenue growth is solid, though it faces competition in the postsurgical pain management market.
• ZILRETTA's 4% growth is consistent with the market for intra-articular corticosteroids for osteoarthritis, which is a mature but substantial market.
• The divestiture of iovera to Zimmer Biomet, a major medical technology company, suggests a strategic refocusing that is common among biopharmaceutical firms seeking to optimize their portfolios.
• The development of PCRX-201, a gene therapy for osteoarthritis, places Pacira at the forefront of innovation in a field where few companies have achieved significant clinical success or regulatory designations like RMAT and ATMP for this indication.

Legal Proceedings

• Settlement of patent infringement lawsuits against Fresenius Kabi USA, LLC, eVenus Pharmaceuticals Laboratories, Inc., and Jiangsu Hengrui Pharmaceuticals Co., Ltd. in the six months ended June 30, 2025, for $7.0 million.

Stakeholder Impact

• Shareholders: The report shows continued revenue growth and strategic progress, but a decrease in adjusted EBITDA may temper short-term sentiment. The iovera divestiture aims to sharpen focus and potentially unlock value.
• Patients: Expanded reimbursement for EXPAREL by UnitedHealthcare improves access to non-opioid pain management options.
• Healthcare Providers: Continued adoption of EXPAREL and ZILRETTA, supported by real-world data and reimbursement changes, benefits providers seeking effective pain management solutions.
• Zimmer Biomet: The successful closing of the iovera divestiture is a key event for both companies, with Pacira retaining potential upside.

Next Steps

• Continue execution of the 5x30 strategy.
• Advance the PCRX-201 development program, with topline data from Part A of the Phase 2 ASCEND study expected by the end of 2026.
• Monitor the publication of the Phase 1 study of PCRX-201 in Annals of the Rheumatic Diseases.
• Continue to expand access to EXPAREL through reimbursement initiatives.
• Potentially receive incremental compensation from Zimmer Biomet for the spasticity program, assuming successful completion of studies and regulatory approval.

Key Dates

Recommendation

The report shows steady revenue growth and strategic advancements, particularly with EXPAREL's expanded reimbursement and the progress of PCRX-201. However, the decrease in adjusted EBITDA and non-GAAP net income compared to the prior year, coupled with a slight reduction in full-year revenue guidance, suggests a period of consolidation rather than strong acceleration. The company is well-positioned in its core markets, but significant catalysts for a 'buy' rating are not yet evident in this report.

Keywords

EXPAREL, ZILRETTA, non-opioid pain therapies, osteoarthritis, gene therapy, PCRX-201, financial results, revenue growth